Predominant Androgenic Component in the Induction of Erythropoietin-Hypersecretory State by 19-Nortestosterone in the Orchidectomised Mouse

Erythropoietin-hypersecretory state (EPO-HS) has been defined as a condition, easily observed in hypertransfused-polycythaemic rats and mice as a consequence of several treatments, in which hypoxia-stimulated secretion of EPO is higher than in non-treated polycythaemic controls at equal levels of po...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Comparative clinical pathology 2002-04, Vol.11 (2), p.107-112
Hauptverfasser: CONTI, M. I., MARTI´NEZ, M. P., BARCELO´, A. C., CHAMPIN, G. M., ALIPPI, R. M., BOZZINI, C. E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 112
container_issue 2
container_start_page 107
container_title Comparative clinical pathology
container_volume 11
creator CONTI, M. I.
MARTI´NEZ, M. P.
BARCELO´, A. C.
CHAMPIN, G. M.
ALIPPI, R. M.
BOZZINI, C. E.
description Erythropoietin-hypersecretory state (EPO-HS) has been defined as a condition, easily observed in hypertransfused-polycythaemic rats and mice as a consequence of several treatments, in which hypoxia-stimulated secretion of EPO is higher than in non-treated polycythaemic controls at equal levels of polycythaemia. Testosterone is a potent inducer of EPO-HS. Some steroids, such as 19-nortestosterone (19-NT) have a stronger anabolic activity, relative to androgenic activity, than others. All of them, however, induce almost the same degree of erythropoiesis in the polycythaemic mouse model. The present study was carried out to test the capacity of 19-NT to induce an EPO-HS and to establish which of the androgenic or anabolic activities is the predominant component in the erythropoietic action of the steroid. Seventy CF-1 mice were orchidectomised when aged 30 days. One month later, groups of 10 animals were injected s.c. 3 times a week for 4 weeks with 19-NT at doses of 0, 50, 100, 200, 400, 800, 1600 and 3200 μg/days. A group of entire male mice was used as normal controls. All mice were hypertransfused 4 days after the end of the injection period. On the next day, they were exposed to 506.5 mbar for 6 h. Plasma EPO titre (ELISA Medac Diagnostika, FRG) was determined and taken as a reflection of the EPO-production rate. Kidney, seminal vesicle and levator ani muscle weights were registered as index of renotrophic, androgenic and anabolic effects, respectively. EPO production in response to hypoxia increased with increased doses of 19-NT. The derived linear regression between plasma EPO (mU/ml) and 19-NT log dose showed the following characteristics: slope, 42.50 ± 6.82; y-int., -50.68 ± 18.2; x-int., 1.192; r^sup 2^, 0.8861; p 0.0016. Positive correlations were found between EPO production and kidney weight (r 0.8995, r^sup 2^ 0.8092, p 0.0023), seminal vesicle weight (r 0.9213, r^sup 2^0.8489, p 0.0011) and levator ani muscle weight (r0.6851, r^sup 2^ 0.4694, p 0.0608). 19-NT thus induced an EPO-HS in orchidectomised mice when administered in pharmacological doses. This capacity was associated with renotrophic and androgenic effects of the steroid and apparently not related to its anabolic activity.[PUBLICATION ABSTRACT]
doi_str_mv 10.1007/s005800200007
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1112234002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2789637851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c178t-393e4ccbd6a93bc35215f0351a4eb404334f5cccf81d4888f9d2a32bf4fa04f13</originalsourceid><addsrcrecordid>eNpVkEFLAzEQhYMoWKtH7wHPq8kmabPHUqotVCuo4G3ZTSY2xSZrkj3sb_BPG6kKzmWG4fG9x0PokpJrSsj0JhIiJCElyTM9QiM6obIQE_F6_HdzeorOYtwRQoVkbIQ-HwNov7eucQnPnA7-DZxVeO73nXeQn9bhtAW8crpXyXqHvcGLMKRt8J23kKwrlkMHIYIKkHwY8FNqEuB2wLQqHnxIEJOPCULm_dI2QW2tBpWydQSN730f4RydmOY9wsXPHqOX28XzfFmsN3er-WxdKDqVqWAVA65UqydNxVrFREmFIUzQhkPLCWeMG6GUMpJqLqU0lS4bVraGm4ZwQ9kYXR24XfAffU5X73wfXLasKaVlyXguMauKg0oFH2MAU3fB7psw1JTU333X__pmXy3FdZk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1112234002</pqid></control><display><type>article</type><title>Predominant Androgenic Component in the Induction of Erythropoietin-Hypersecretory State by 19-Nortestosterone in the Orchidectomised Mouse</title><source>SpringerNature Journals</source><creator>CONTI, M. I. ; MARTI´NEZ, M. P. ; BARCELO´, A. C. ; CHAMPIN, G. M. ; ALIPPI, R. M. ; BOZZINI, C. E.</creator><creatorcontrib>CONTI, M. I. ; MARTI´NEZ, M. P. ; BARCELO´, A. C. ; CHAMPIN, G. M. ; ALIPPI, R. M. ; BOZZINI, C. E.</creatorcontrib><description>Erythropoietin-hypersecretory state (EPO-HS) has been defined as a condition, easily observed in hypertransfused-polycythaemic rats and mice as a consequence of several treatments, in which hypoxia-stimulated secretion of EPO is higher than in non-treated polycythaemic controls at equal levels of polycythaemia. Testosterone is a potent inducer of EPO-HS. Some steroids, such as 19-nortestosterone (19-NT) have a stronger anabolic activity, relative to androgenic activity, than others. All of them, however, induce almost the same degree of erythropoiesis in the polycythaemic mouse model. The present study was carried out to test the capacity of 19-NT to induce an EPO-HS and to establish which of the androgenic or anabolic activities is the predominant component in the erythropoietic action of the steroid. Seventy CF-1 mice were orchidectomised when aged 30 days. One month later, groups of 10 animals were injected s.c. 3 times a week for 4 weeks with 19-NT at doses of 0, 50, 100, 200, 400, 800, 1600 and 3200 μg/days. A group of entire male mice was used as normal controls. All mice were hypertransfused 4 days after the end of the injection period. On the next day, they were exposed to 506.5 mbar for 6 h. Plasma EPO titre (ELISA Medac Diagnostika, FRG) was determined and taken as a reflection of the EPO-production rate. Kidney, seminal vesicle and levator ani muscle weights were registered as index of renotrophic, androgenic and anabolic effects, respectively. EPO production in response to hypoxia increased with increased doses of 19-NT. The derived linear regression between plasma EPO (mU/ml) and 19-NT log dose showed the following characteristics: slope, 42.50 ± 6.82; y-int., -50.68 ± 18.2; x-int., 1.192; r^sup 2^, 0.8861; p 0.0016. Positive correlations were found between EPO production and kidney weight (r 0.8995, r^sup 2^ 0.8092, p 0.0023), seminal vesicle weight (r 0.9213, r^sup 2^0.8489, p 0.0011) and levator ani muscle weight (r0.6851, r^sup 2^ 0.4694, p 0.0608). 19-NT thus induced an EPO-HS in orchidectomised mice when administered in pharmacological doses. This capacity was associated with renotrophic and androgenic effects of the steroid and apparently not related to its anabolic activity.[PUBLICATION ABSTRACT]</description><identifier>ISSN: 1618-5641</identifier><identifier>EISSN: 1618-565X</identifier><identifier>DOI: 10.1007/s005800200007</identifier><language>eng</language><publisher>London: Springer Nature B.V</publisher><subject>Hypoxia ; Medical research ; Rodents</subject><ispartof>Comparative clinical pathology, 2002-04, Vol.11 (2), p.107-112</ispartof><rights>Springer-Verlag London Limited 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c178t-393e4ccbd6a93bc35215f0351a4eb404334f5cccf81d4888f9d2a32bf4fa04f13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>CONTI, M. I.</creatorcontrib><creatorcontrib>MARTI´NEZ, M. P.</creatorcontrib><creatorcontrib>BARCELO´, A. C.</creatorcontrib><creatorcontrib>CHAMPIN, G. M.</creatorcontrib><creatorcontrib>ALIPPI, R. M.</creatorcontrib><creatorcontrib>BOZZINI, C. E.</creatorcontrib><title>Predominant Androgenic Component in the Induction of Erythropoietin-Hypersecretory State by 19-Nortestosterone in the Orchidectomised Mouse</title><title>Comparative clinical pathology</title><description>Erythropoietin-hypersecretory state (EPO-HS) has been defined as a condition, easily observed in hypertransfused-polycythaemic rats and mice as a consequence of several treatments, in which hypoxia-stimulated secretion of EPO is higher than in non-treated polycythaemic controls at equal levels of polycythaemia. Testosterone is a potent inducer of EPO-HS. Some steroids, such as 19-nortestosterone (19-NT) have a stronger anabolic activity, relative to androgenic activity, than others. All of them, however, induce almost the same degree of erythropoiesis in the polycythaemic mouse model. The present study was carried out to test the capacity of 19-NT to induce an EPO-HS and to establish which of the androgenic or anabolic activities is the predominant component in the erythropoietic action of the steroid. Seventy CF-1 mice were orchidectomised when aged 30 days. One month later, groups of 10 animals were injected s.c. 3 times a week for 4 weeks with 19-NT at doses of 0, 50, 100, 200, 400, 800, 1600 and 3200 μg/days. A group of entire male mice was used as normal controls. All mice were hypertransfused 4 days after the end of the injection period. On the next day, they were exposed to 506.5 mbar for 6 h. Plasma EPO titre (ELISA Medac Diagnostika, FRG) was determined and taken as a reflection of the EPO-production rate. Kidney, seminal vesicle and levator ani muscle weights were registered as index of renotrophic, androgenic and anabolic effects, respectively. EPO production in response to hypoxia increased with increased doses of 19-NT. The derived linear regression between plasma EPO (mU/ml) and 19-NT log dose showed the following characteristics: slope, 42.50 ± 6.82; y-int., -50.68 ± 18.2; x-int., 1.192; r^sup 2^, 0.8861; p 0.0016. Positive correlations were found between EPO production and kidney weight (r 0.8995, r^sup 2^ 0.8092, p 0.0023), seminal vesicle weight (r 0.9213, r^sup 2^0.8489, p 0.0011) and levator ani muscle weight (r0.6851, r^sup 2^ 0.4694, p 0.0608). 19-NT thus induced an EPO-HS in orchidectomised mice when administered in pharmacological doses. This capacity was associated with renotrophic and androgenic effects of the steroid and apparently not related to its anabolic activity.[PUBLICATION ABSTRACT]</description><subject>Hypoxia</subject><subject>Medical research</subject><subject>Rodents</subject><issn>1618-5641</issn><issn>1618-565X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpVkEFLAzEQhYMoWKtH7wHPq8kmabPHUqotVCuo4G3ZTSY2xSZrkj3sb_BPG6kKzmWG4fG9x0PokpJrSsj0JhIiJCElyTM9QiM6obIQE_F6_HdzeorOYtwRQoVkbIQ-HwNov7eucQnPnA7-DZxVeO73nXeQn9bhtAW8crpXyXqHvcGLMKRt8J23kKwrlkMHIYIKkHwY8FNqEuB2wLQqHnxIEJOPCULm_dI2QW2tBpWydQSN730f4RydmOY9wsXPHqOX28XzfFmsN3er-WxdKDqVqWAVA65UqydNxVrFREmFIUzQhkPLCWeMG6GUMpJqLqU0lS4bVraGm4ZwQ9kYXR24XfAffU5X73wfXLasKaVlyXguMauKg0oFH2MAU3fB7psw1JTU333X__pmXy3FdZk</recordid><startdate>200204</startdate><enddate>200204</enddate><creator>CONTI, M. I.</creator><creator>MARTI´NEZ, M. P.</creator><creator>BARCELO´, A. C.</creator><creator>CHAMPIN, G. M.</creator><creator>ALIPPI, R. M.</creator><creator>BOZZINI, C. E.</creator><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200204</creationdate><title>Predominant Androgenic Component in the Induction of Erythropoietin-Hypersecretory State by 19-Nortestosterone in the Orchidectomised Mouse</title><author>CONTI, M. I. ; MARTI´NEZ, M. P. ; BARCELO´, A. C. ; CHAMPIN, G. M. ; ALIPPI, R. M. ; BOZZINI, C. E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c178t-393e4ccbd6a93bc35215f0351a4eb404334f5cccf81d4888f9d2a32bf4fa04f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Hypoxia</topic><topic>Medical research</topic><topic>Rodents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CONTI, M. I.</creatorcontrib><creatorcontrib>MARTI´NEZ, M. P.</creatorcontrib><creatorcontrib>BARCELO´, A. C.</creatorcontrib><creatorcontrib>CHAMPIN, G. M.</creatorcontrib><creatorcontrib>ALIPPI, R. M.</creatorcontrib><creatorcontrib>BOZZINI, C. E.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Comparative clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CONTI, M. I.</au><au>MARTI´NEZ, M. P.</au><au>BARCELO´, A. C.</au><au>CHAMPIN, G. M.</au><au>ALIPPI, R. M.</au><au>BOZZINI, C. E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predominant Androgenic Component in the Induction of Erythropoietin-Hypersecretory State by 19-Nortestosterone in the Orchidectomised Mouse</atitle><jtitle>Comparative clinical pathology</jtitle><date>2002-04</date><risdate>2002</risdate><volume>11</volume><issue>2</issue><spage>107</spage><epage>112</epage><pages>107-112</pages><issn>1618-5641</issn><eissn>1618-565X</eissn><abstract>Erythropoietin-hypersecretory state (EPO-HS) has been defined as a condition, easily observed in hypertransfused-polycythaemic rats and mice as a consequence of several treatments, in which hypoxia-stimulated secretion of EPO is higher than in non-treated polycythaemic controls at equal levels of polycythaemia. Testosterone is a potent inducer of EPO-HS. Some steroids, such as 19-nortestosterone (19-NT) have a stronger anabolic activity, relative to androgenic activity, than others. All of them, however, induce almost the same degree of erythropoiesis in the polycythaemic mouse model. The present study was carried out to test the capacity of 19-NT to induce an EPO-HS and to establish which of the androgenic or anabolic activities is the predominant component in the erythropoietic action of the steroid. Seventy CF-1 mice were orchidectomised when aged 30 days. One month later, groups of 10 animals were injected s.c. 3 times a week for 4 weeks with 19-NT at doses of 0, 50, 100, 200, 400, 800, 1600 and 3200 μg/days. A group of entire male mice was used as normal controls. All mice were hypertransfused 4 days after the end of the injection period. On the next day, they were exposed to 506.5 mbar for 6 h. Plasma EPO titre (ELISA Medac Diagnostika, FRG) was determined and taken as a reflection of the EPO-production rate. Kidney, seminal vesicle and levator ani muscle weights were registered as index of renotrophic, androgenic and anabolic effects, respectively. EPO production in response to hypoxia increased with increased doses of 19-NT. The derived linear regression between plasma EPO (mU/ml) and 19-NT log dose showed the following characteristics: slope, 42.50 ± 6.82; y-int., -50.68 ± 18.2; x-int., 1.192; r^sup 2^, 0.8861; p 0.0016. Positive correlations were found between EPO production and kidney weight (r 0.8995, r^sup 2^ 0.8092, p 0.0023), seminal vesicle weight (r 0.9213, r^sup 2^0.8489, p 0.0011) and levator ani muscle weight (r0.6851, r^sup 2^ 0.4694, p 0.0608). 19-NT thus induced an EPO-HS in orchidectomised mice when administered in pharmacological doses. This capacity was associated with renotrophic and androgenic effects of the steroid and apparently not related to its anabolic activity.[PUBLICATION ABSTRACT]</abstract><cop>London</cop><pub>Springer Nature B.V</pub><doi>10.1007/s005800200007</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1618-5641
ispartof Comparative clinical pathology, 2002-04, Vol.11 (2), p.107-112
issn 1618-5641
1618-565X
language eng
recordid cdi_proquest_journals_1112234002
source SpringerNature Journals
subjects Hypoxia
Medical research
Rodents
title Predominant Androgenic Component in the Induction of Erythropoietin-Hypersecretory State by 19-Nortestosterone in the Orchidectomised Mouse
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A12%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predominant%20Androgenic%20Component%20in%20the%20Induction%20of%20Erythropoietin-Hypersecretory%20State%20by%2019-Nortestosterone%20in%20the%20Orchidectomised%20Mouse&rft.jtitle=Comparative%20clinical%20pathology&rft.au=CONTI,%20M.%20I.&rft.date=2002-04&rft.volume=11&rft.issue=2&rft.spage=107&rft.epage=112&rft.pages=107-112&rft.issn=1618-5641&rft.eissn=1618-565X&rft_id=info:doi/10.1007/s005800200007&rft_dat=%3Cproquest_cross%3E2789637851%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1112234002&rft_id=info:pmid/&rfr_iscdi=true